conclusions this study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that her2/neu is not a unique strong predictor for outcome, thus according to combination of her2/neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence. results her2/neu amplification was identified in 19 (38%) of 50 patients. no...

Background: Amplification of HER2 is seen in 20-30% of breast cancer cases. Measurement of HER2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. The aim of our study was to evaluate HER2 amplification status in malignant and benign breast tumors by differential PCR (dPCR). Materials and Methods: The genomic DNA was ex...

background: one million people are diagnosed with gastric cancer (gc) annually and the prognosis for patients with advanced gc or gastroesophageal junction (gej) cancer is usually poor with a median survival time of 8 to 10 months. recent reports have identified that anti her2 target therapy improved the median survival rate in patients with her2 positive gc; but a wide range of her2 overexpres...

Shedding of a pharmacological target from cells, giving rise to a soluble target that can also bind therapeutic proteins, is a common phenomenon. In this study, a minimal physiologically based pharmacokinetic model was used to simulate the pharmacokinetics of trastuzumab and the simultaneous binding of the compound to soluble (in blood and tissue interstitial space) and membrane-bound (in the t...

JCC76 is a derivative of cyclooxygenase-2(COX-2) selective inhibitor nimesulide and exhibits potent anti-breast cancer activity. It selectively induces apoptosis of Her2 positive breast cancer cells. However, the specific molecular targets of JCC76 still remain unclear, which significantly withdraw the further drug development of JCC76. To identify the molecular targets of JCC76, a six carbon l...

introduction: trastuzumab is a monoclonal antibody that is used in treating breast cancer. we labeled this monoclonal antibody with technetium-99m and performed in vitro and in vivo quality control tests as a first step in the production of a new radiopharmaceutical. methods: trastuzumab was labeled with technetium-99m using succinimidyl hydrazinonicotinamide (hynic) as chelator. radiochemical ...

PURPOSE Allogeneic glioma cell lines that are partially matched to the patient at class I human leukocyte antigen (HLA) loci and that display tumor-associated antigens (TAA) or antigenic precursors [tumor antigen precursor proteins (TAPP)] could be used for generating whole tumor cell vaccines or, alternatively, for extraction of TAA peptides to make autologous dendritic cell vaccines. EXPERI...

Trans-Scirpusin A (TSA) is a resveratrol oligomer found in Borassus flabellifer L. We found that TSA inhibited the growth of colorectal cancer Her2/CT26 cells in vivo in mice. Although some cytotoxic T lymphocytes (CTLs) were induced against the tumor-associated antigen Her2, TSA treatment did not significantly increase the level of Her2-specific CTL response compared to that with vehicle treat...